Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06901622 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
Trial Details
NCT Number NCT06901622
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions
(from sponsor)		 Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Related terms Cholangiocarcinoma, Gallbladder Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov